Table II.
Demographics and Efficacy of Nilotinib (ENESTnd trial)
Nilotinib 300mg twice daily (n= 282) | Nilotinib 400mg twice daily (n= 281) | Imatinib 400mg once daily (n=283) | |
---|---|---|---|
Median duration of treatment | 13.8 months | 13.8 months | 13.8 months |
Median age Range | 47 years (18-85 years) | 47 years (18-81 years) | 46 years (18-80 years) |
Sokal Risk (%) | |||
Low | 37 | 37 | 37 |
Intermediate | 36 | 36 | 36 |
High | 28 | 28 | 28 |
Prior Imatinb (%) | 13 | 9 | 11 |
MMR (%) | |||
By 6 months | 44 | 43 | 22 (P<0.001, <0.001) |
By 12 months | 55 | 51 | 27 (P<0.001, <0.001) |
Confirmed CCyR (%) | |||
By 6 months | 67 | 63 | 45 (P=NR) |
By 12 months | 80 | 78 | 72 (P<0.0001, <0.0005) |
(Adapted, with permission, from Saglio et al, Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia, NEngl J Med, 2010;362:2251-2259)